Feasibility of Oto-acoustic Emission assessment in identification of early and significant ototoxic hearing loss in pediatric cancer patients receiving Cisplatin based Chemotherapy

Tata Research Administrative Council0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年9月18日

试验速览

暂无简介。

•Following are the inclusion criteria for enrollment of the study participants.
•1.Pediatric cancer patients who are planned to receive Cisplatin based chemotherapy
•2.Pediatric cancer patients who must be within the age range of 3-17 years
•3.Pediatric cancer patients who must be able to provide consistent and reliable responses in conventional pure-tone audiometry
•4.Pediatric cancer patients who must present with normal OAE findings at all the test frequencies; i.e. I. For TEAOE, SNR equal to or greater than 6dBSPLand TEOAE level equal to or greater than 0 dBSPL at all the test frequencies with a minimum overall reproducibility rate of 80%; II. For DPOAE, SNR equal to or greater than 6 dBSPL and DPOAE level equal to or greater than 0 dBSPL with a minimum DP reliability rate of 98%based on DP tolerance level ±2 at all the test frequencies.

•Following ear-wise exclusion criteria at the time of enrollment will be taken for the study.
•1.Pediatric cancer patients with any middle ear pathology or previous ear surgery
•2.Pediatric cancer patients with any known pre-treatment hearing loss documented in baseline audiogram.
•3.Pediatric cancer patients with any known cognitive or psychological problems
•4.Pediatric cancer patients with any known ototoxic cancer treatment before.
•5.Pediatric cancer patients who are planned for cranial radiation therapy

发起方

Tata Research Administrative Council